Univariate analysis revealed that, compared with luminal A breast cancer, patients had significantly increased HRs for OS with luminal B (HR 1.9; P = 0.02), HER2-positive (HR 3.2; P < 0.001), and TNBC (HR 3.3; P < 0.001) (Fig. 1). This evidence concerns the gene ERBB2 and breast cancer.